SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR FOR TREATING HCV GT1 INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE: THE RUBY-I STUDY

被引：46

作者：

Pockros, P. J. ^{[1
]}

Reddy, K. R. ^{[2
]}

Mantry, P. S. ^{[3
]}

Cohen, E. ^{[4
]}

Bennett, M. ^{[5
]}

Sulkowski, M. S. ^{[6
]}

Bernstein, D. ^{[7
]}

Podsadecki, T. ^{[4
]}

Cohen, D. ^{[4
]}

Shulman, N. S. ^{[4
]}

Wang, D. ^{[4
]}

Khatri, A. ^{[4
]}

Abunimeh, M. ^{[4
]}

Lawitz, E. ^{[8
]}

机构：

[1] Scripps Clin, La Jolla, CA 92037 USA

[2] Univ Penn, Philadelphia, PA 19104 USA

[3] Methodist Dallas, Liver Inst, Dallas, TX USA

[4] AbbVie Inc, N Chicago, IL USA

[5] Med Associates Res Grp, San Diego, CA USA

[6] Johns Hopkins Univ, Baltimore, MD USA

[7] N Shore Univ Hosp, Manhasset, NY USA

[8] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA

来源：

关键词：

D O I：

10.1016/S0168-8278(15)30147-1

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

LO1

引用

页码：S257 / S257

页数：1